Prohost Letter #377

Prohost Letter #377
Before Investing in Them

Raising the bar in designating small drug developing firms as biotechnology firms has occurred several times since 2011. In that year, many technologies were tremendously enhanced, which enabled them to realize superior goals, i.e., produce safer and more effective breakthrough drugs for chronic debilitating and life-threatening diseases.
Prohost Portfolios picks, which have outperformed other industries’ firms were selected around the first quarter of 2011. At that time, we picked for investment the antisense group and the cancer developing firms; we repicked the top-tier . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.